Essential thrombocytosis laboratory findings: Difference between revisions
(Created page with "{{Essential thrombocytosis}} {{CMG}} ==Overview== ==References== {{reflist|2}} Category:Disease Category:Types of cancer Category:Hematology [[Category:Oncolog...") |
No edit summary |
||
(19 intermediate revisions by 3 users not shown) | |||
Line 1: | Line 1: | ||
__NOTOC__ | |||
{{Essential thrombocytosis}} | {{Essential thrombocytosis}} | ||
{{CMG}} | {{CMG}}{{AE}} {{STM}} | ||
==Overview== | ==Overview== | ||
Laboratory findings consistent with the diagnosis of essential thrombocytosis include abnormal complete blood count (elevated platelet count, leukocytosis, erythrocytosis), peripheral blood smear showing large platelets, megakaryocyte fragments and platelet aggregates, presence of ''[[JAK2]]'' mutation, and absence of ''BCR-ABL'' or [[Philadelphia chromosome]].<ref name="pmid16879015">{{cite journal| author=Sanchez S, Ewton A| title=Essential thrombocythemia: a review of diagnostic and pathologic features. | journal=Arch Pathol Lab Med | year= 2006 | volume= 130 | issue= 8 | pages= 1144-50 | pmid=16879015 | doi=10.1043/1543-2165(2006)130[1144:ET]2.0.CO;2 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=16879015 }} </ref><ref name=re>Essential Thrombocythemia. Merck manual. http://www.merckmanuals.com/professional/hematology-and-oncology/myeloproliferative-disorders/essential-thrombocythemia. Accessed on November 11,2015.</ref> | |||
==Laboratory findings== | |||
Essential thrombocytosis remains a diagnosis of exclusion, after ruling out reactive or secondary causes of thrombocytosis. Laboratory tests for the diagnosis of essential thrombocytosis include the following:<ref name="pmid16879015">{{cite journal| author=Sanchez S, Ewton A| title=Essential thrombocythemia: a review of diagnostic and pathologic features. | journal=Arch Pathol Lab Med | year= 2006 | volume= 130 | issue= 8 | pages= 1144-50 | pmid=16879015 | doi=10.1043/1543-2165(2006)130[1144:ET]2.0.CO;2 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=16879015 }} </ref> | |||
*Complete blood count ([[CBC]]) | |||
**Elevated platelet count | |||
**[[Leukocytosis]] and [[erythrocytosis]] may be present | |||
**Red cells are [[normocytic]] and [[normochromic]], unless the patient had significant hemorrhage. | |||
*Peripheral blood smear shows large platelets, megakaryocyte fragments and platelet aggregates.<ref name=re>Essential Thrombocythemia. Merck manual. http://www.merckmanuals.com/professional/hematology-and-oncology/myeloproliferative-disorders/essential-thrombocythemia. Accessed on November 11,2015.</ref> | |||
*To rule out inflammatory disorders | |||
**Erythrocyte sedimentation rate ([[ESR]]) (normal in essential thrombocytosis) | |||
**C-reactive protein ([[CRP]]) (normal in essential thrombocytosis) | |||
**[[Fibrinogen]] (normal in essential thrombocytosis) | |||
*To rule out iron deficiency and [[polycythemia vera]] | |||
**Serum [[ferritin]] (normal in essential thrombocytosis) | |||
**[[Hematocrit]] (normal in essential thrombocytosis) | |||
==Genetic Testing== | |||
*To rule out other myeloproliferative neoplasms | |||
**''BCR-ABL'' or [[Philadelphia chromosome]] | |||
*To check for genetic mutations | |||
**''JAK2'' mutation using [[PCR]] | |||
==References== | ==References== | ||
Line 9: | Line 32: | ||
[[Category:Disease]] | [[Category:Disease]] | ||
[[Category:Types of cancer]] | [[Category:Types of cancer]] | ||
[[Category:Hematology]] | [[Category:Hematology]] | ||
{{WikiDoc Help Menu}} | {{WikiDoc Help Menu}} | ||
{{WikiDoc Sources}} | {{WikiDoc Sources}} |
Latest revision as of 19:50, 6 January 2016
Essential thrombocytosis Microchapters |
Differentiating Essential thrombocytosis from other Diseases |
---|
Diagnosis |
Treatment |
Essential thrombocytosis laboratory findings On the Web |
American Roentgen Ray Society Images of Essential thrombocytosis laboratory findings |
Risk calculators and risk factors for Essential thrombocytosis laboratory findings |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Soujanya Thummathati, MBBS [2]
Overview
Laboratory findings consistent with the diagnosis of essential thrombocytosis include abnormal complete blood count (elevated platelet count, leukocytosis, erythrocytosis), peripheral blood smear showing large platelets, megakaryocyte fragments and platelet aggregates, presence of JAK2 mutation, and absence of BCR-ABL or Philadelphia chromosome.[1][2]
Laboratory findings
Essential thrombocytosis remains a diagnosis of exclusion, after ruling out reactive or secondary causes of thrombocytosis. Laboratory tests for the diagnosis of essential thrombocytosis include the following:[1]
- Complete blood count (CBC)
- Elevated platelet count
- Leukocytosis and erythrocytosis may be present
- Red cells are normocytic and normochromic, unless the patient had significant hemorrhage.
- Peripheral blood smear shows large platelets, megakaryocyte fragments and platelet aggregates.[2]
- To rule out inflammatory disorders
- Erythrocyte sedimentation rate (ESR) (normal in essential thrombocytosis)
- C-reactive protein (CRP) (normal in essential thrombocytosis)
- Fibrinogen (normal in essential thrombocytosis)
- To rule out iron deficiency and polycythemia vera
- Serum ferritin (normal in essential thrombocytosis)
- Hematocrit (normal in essential thrombocytosis)
Genetic Testing
- To rule out other myeloproliferative neoplasms
- BCR-ABL or Philadelphia chromosome
- To check for genetic mutations
- JAK2 mutation using PCR
References
- ↑ 1.0 1.1 Sanchez S, Ewton A (2006). "Essential thrombocythemia: a review of diagnostic and pathologic features". Arch Pathol Lab Med. 130 (8): 1144–50. doi:10.1043/1543-2165(2006)130[1144:ET]2.0.CO;2. PMID 16879015.
- ↑ 2.0 2.1 Essential Thrombocythemia. Merck manual. http://www.merckmanuals.com/professional/hematology-and-oncology/myeloproliferative-disorders/essential-thrombocythemia. Accessed on November 11,2015.